-
1.发明公开2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents 审中-公开2,4,5- triphenylimidazolinderivate作为用作抗癌剂p53和MDM2蛋白之间相互作用的抑制剂
公开(公告)号：EP2130822A1
公开(公告)日：2009-12-09
申请号：EP09166803.8
申请日：2006-11-22
发明人： Ding, Qingjie , Graves, Bradford James , Kong, Norman , Liu, Jin-Jun , Lovey, Allen John , Pizzolato, Giacomo , Roberts, John Lawson , So, Sung-Sau , Vu, Binh Thanh , Wovkulich, Peter Michael
IPC分类号： C07D233/22 , C07D233/26 , C07D401/06 , C07D403/06 , C07D407/12 , C07D409/12 , C07D471/04 , C07D487/04 , A61K31/4164 , A61K31/496 , A61P35/00
CPC分类号： C07D233/22 , C07D233/26 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D407/12 , C07D409/12 , C07D417/12 , C07D471/04 , C07D487/04
摘要： The present invention relates to compounds of formula I
and the pharmaceutically acceptable salts and esters thereof wherein X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined as in claim. The compounds exhibit activity as anticancer agents.摘要翻译： 本发明涉及I和药学上可接受的盐和酯worin X 1，X 2，R 1，R 2，R 3，R 4，R 5和R 6的定义如claimsoft式I化合物。 化合物显示出活性的抗癌剂。
-
2.发明公开2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents 审中-公开2,4,5- Triphenylimidazolinderivate如p53和MDM2蛋白之间相互作用的抑制剂，用作抗癌剂
公开(公告)号：EP2311814A1
公开(公告)日：2011-04-20
申请号：EP10175570.0
申请日：2006-11-22
发明人： Ding, Qingjie , Graves, Bradford James , Kong, Norman , Liu, Jin-Jun , Lovey, Allen John , Pizzolato, Giacomo , Roberts, John Lawson , So, Sung-Sau , Vu, Binh Thanh , Wovkulich, Peter Michael
IPC分类号： C07D233/22 , C07D233/26 , C07D401/06 , C07D403/06 , C07D407/12 , C07D409/12 , C07D471/04 , C07D487/04 , A61K31/4164 , A61K31/496 , A61P35/00
CPC分类号： C07D233/22 , C07D233/26 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D407/12 , C07D409/12 , C07D417/12 , C07D471/04 , C07D487/04
摘要： There is provided a compound of formula I
and the pharmaceutically acceptable salts and esters thereof wherein X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are herein described. The compounds exhibit activity as anticancer agents.摘要翻译： 本发明提供式I的化合物和药学上可接受的盐和酯，其中X 1，X 2，R 1，R 2，R 3，R 4，R 5和R 6中描述。 化合物显示出活性的抗癌剂。
-
公开(公告)号：EP2325180A1
公开(公告)日：2011-05-25
申请号：EP10175975.1
申请日：2008-09-30
发明人： Bartkovitz, David Joseph , Cai, Jianping , Chu, Xin-Jie , Li, Hongju , Lovey, Allen John , Vu, Binh Thanh , Zhao, Chunlin
IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , A61K31/454 , A61P35/00
CPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/10
摘要： There are provided compounds of the formula
or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V 3 , V 2 , R 1 , R 2 , R 3 , R 4 and R 5 are as herein described, processes for obtaining said compounds and pharmaceutical preparations containing them. These compounds are useful as anticancer agents, in particular as agents in the treatment of solid tumors.摘要翻译： 提供下式的化合物或其药学上可接受的盐，其中X，Y，Z，V 3，V 2，R 1，R 2，R 3，R 4和R 5如本文所述， 化合物和含有它们的药物制剂。 这些化合物可用作抗癌剂，特别是作为治疗实体瘤的药物。
-
-
搜索结果
3 条记录 (耗时 0.012 秒)
